Article
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Pharmacogenetics and genomics - 1 Dec 2007
Giusti Betti, Gori Anna Maria, Marcucci Rossella, Saracini Claudia, Sestini Ilaria, Paniccia Rita, Valente Serafina, Antoniucci Davide, Abbate Rosanna, Gensini Gian Franco
Abstract excerpt
OBJECTIVES: The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment. BACKGROUND: Residual platelet reactivity (RPR) phenomenon on antiplatelet therapy requires clarification. P2Y12 T744C, CYP3A4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.